- Valuation in line with peers
- Oncology sales up more than a quarter
AstraZeneca's (AZN) strong first-quarter (Q1) update has silenced, for now, many of the bears who came out in force after its FY2023 results. Sales of $12.7bn (£10.1bn) were 7 per cent ahead of analyst consensus – and 19 per cent higher than the same period last year.